|Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.|
|PMID: 9746789 Owner: NLM Status: MEDLINE|
|Theophylline, a drug known to inhibit several classes of adenosine 3'5' cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis in chronic lymphocytic leukemia (CLL) cells. Because the PDE target for theophylline in CLL remains unknown, we examined the ability of isoform-specific PDE inhibitors to increase cAMP levels and induce apoptosis in primary CLL cells. Reverse transcriptase-polymerase chain reaction of purified CLL cDNA amplified transcripts for PDE1B, 4A and 4B. The type 4 PDE inhibitor rolipram but not the type 1 inhibitor vinpocetine increased CLL cAMP levels. Rolipram-inhibitable (type 4) but not calcium-calmodulin augmented (type 1) PDE enzyme activity was detected in CLL samples. In samples from 13 of 14 CLL patients, rolipram induced apoptosis in a dose-dependent fashion over a 48-hour period. Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig stimulated CD19(+) B cells were resistant to the induction of apoptosis by rolipram while unstimulated CD19(+) B cells, which had a high basal apoptotic rate, were more sensitive. Rolipram stimulated elevations in cAMP levels in all four of these cell populations, suggesting that they differed in sensitivity to cAMP-induced apoptosis. Consistent with this hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP induced apoptosis in CLL cells and unstimulated B cells but not in IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify PDE4 as a family of enzymes whose inhibition induces apoptosis in CLL cells.|
|D H Kim; A Lerner|
Related Documents :
|6325479 - Control of cell mobility by cyclic amp.
2153559 - Modulators of cyclic amp metabolism induce syncytiotrophoblast formation in vitro.
2579719 - Ultrastructural morphometry and secretory behavior of acinic cell carcinoma.
212849 - Estrogen synthetase in choriocarcinoma cell culture. stimulation by dibutyryl cyclic ad...
9175719 - Dissociation between phosphodiesterase inhibition and antiproliferative effects of phos...
3422429 - Isolation of 1-monomethylphosphoinositol 4,5-bisphosphate [a product of methanolysis of...
24947819 - Epigenetic regulation by chromatin activation mark h3k4me3 in primate progenitor cells ...
23387819 - Effects of phosphorus starvation versus limitation on the marine cyanobacterium prochlo...
12898419 - The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption.
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Blood Volume: 92 ISSN: 0006-4971 ISO Abbreviation: Blood Publication Date: 1998 Oct|
|Created Date: 1998-10-19 Completed Date: 1998-10-19 Revised Date: 2007-11-15|
Medline Journal Info:
|Nlm Unique ID: 7603509 Medline TA: Blood Country: UNITED STATES|
|Languages: eng Pagination: 2484-94 Citation Subset: AIM; IM|
|Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, Boston, MA 02118, USA.|
|APA/MLA Format Download EndNote Download BibTex|
antagonists & inhibitors*
Antibodies, Anti-Idiotypic / pharmacology
Antigens, CD19 / analysis
Antineoplastic Agents / pharmacology*, therapeutic use
Apoptosis / drug effects
B-Lymphocytes / drug effects*, pathology
Bucladesine / pharmacology
Calcium / pharmacology
Calmodulin / metabolism
Cells, Cultured / drug effects
Cyclic AMP / metabolism*
DNA, Complementary / genetics
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Forskolin / pharmacology
Interleukin-2 / pharmacology
Isoenzymes / antagonists & inhibitors*
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*, enzymology, pathology
Leukocytes, Mononuclear / cytology, drug effects
Phosphodiesterase Inhibitors / pharmacology*, therapeutic use
Polymerase Chain Reaction
Pyrrolidinones / pharmacology*, therapeutic use
RNA, Messenger / biosynthesis
Tumor Cells, Cultured / drug effects
Tumor Stem Cell Assay
Vinca Alkaloids / pharmacology*, therapeutic use
|0/Antibodies, Anti-Idiotypic; 0/Antigens, CD19; 0/Antineoplastic Agents; 0/Calmodulin; 0/DNA, Complementary; 0/Interleukin-2; 0/Isoenzymes; 0/Phosphodiesterase Inhibitors; 0/Pyrrolidinones; 0/RNA, Messenger; 0/Vinca Alkaloids; 362-74-3/Bucladesine; 42971-12-0/vinpocetine; 60-92-4/Cyclic AMP; 61413-54-5/Rolipram; 66428-89-5/Forskolin; 7440-70-2/Calcium; EC 18.104.22.168/3',5'-Cyclic-AMP Phosphodiesterases|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in E...
Next Document: Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival.